Key topics

• EU HTA Implementation: Impacts of the EU Health Technology Assessment regulation on market access strategies.
• Innovative Pricing Models: Including outcomes-based pricing, subscription models, and managed entry agreements.
• Global Access and Equity: Strategies to improve access in emerging markets and underserved regions.
• Real-World Evidence (RWE) & Data Use: Enhancing pricing decisions and HTA submissions with real-world data.
• Digital Health & Innovation: The role of digital tools in market access and patient outcomes.
• Rare Diseases & Orphan Drugs: Navigating the unique pricing and access challenges in rare disease treatments.
• Health Economics & Value Frameworks: Evolving value assessments and cost-effectiveness evaluations.
• Patient-Centered Access: Incorporating patient perspectives in access planning and value demonstration.
• Policy Trends & Regulation: Navigating international pricing reforms and evolving policy landscapes.

Who should attend

CEOs / Presidents / MDs, CCOs/CMOs/CDOs, Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:

• Business Development
• Marketing
• Sales
• Pricing
• Market Access
• Medical Director
• Marketing Intelligence
• Drug Pricing
• Product Launch
• Health Economics
• Pricing Policy
• Product Reimbursement
• Health Technology
• Assessment
• Real World Evidence
• Health Informatics
• Data Sciences
• Value Strategy
• P&MA
• Tendering

Target audience

• International and regional health authorities and regulators
• Pharmaceutical, Vaccines, & Biotechnology companies
• Clinical Research Organization (CRO) service providers
• Business Process Outsourcing (BPO) service providers
• Technology Vendors/Portal Service Providers